EPIRUS Biopharmaceuticals (EPRS) Shares are Down -6.45%

EPIRUS Biopharmaceuticals (EPRS) : During the past 4 weeks, traders have been relatively bearish on EPIRUS Biopharmaceuticals (EPRS), hence the stock is down -55.87% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -7.02% relative to the S&P 500. The 4-week change in the price of the stock is -52.89% and the stock has fallen -6.45% in the past 1 week.

EPIRUS Biopharmaceuticals (NASDAQ:EPRS): The stock opened at $0.22 on Friday but the bulls could not build on the opening and the stock topped out at $0.27 for the day. The stock traded down to $0.22 during the day, due to lack of any buying support eventually closed down at $0.25 with a loss of -10.19% for the day. The stock had closed at $0.27 on the previous day. The total traded volume was 1,128,545 shares.


The stock has recorded a 20-day Moving Average of 31.69% and the 50-Day Moving Average is 52.79%. EPIRUS Biopharmaceuticals, Inc. has dropped 92.79% during the last 3-month period . Year-to-Date the stock performance stands at -92.07%.

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a commercial-stage biopharmaceutical company. The Company is engaged in developing, manufacturing, and commercializing biosimilar therapeutics (biosimilars). The Company has a pipeline of operationally synergistic monoclonal antibodies (MAbs) in inflammation and immunology. The Companys lead product candidate, BOW015 is indicated for the treatment of various inflammatory diseases. The Company has launched BOW015 under the brand name, Infimab. The Companys products include BOW015, which contains infliximab; BOW050, which contains adalimumab; BOW070, which contains tocilizumab; BOW080, which contains eculizumab; BOW090, which contains ustekinumab, and BOW100, which contains golimumab.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.